Teva Pharmaceutical Industries (NYSE:TEVA) Updates FY 2026 Earnings Guidance

Posted by Brian Himes on Jul 29th, 2026

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 1.910-2.110 for the period, compared to the consensus EPS estimate of 2.170. The company issued revenue guidance of $16.5 billion-$16.9 billion, compared to the consensus revenue estimate of $16.7 billion.

Analyst Ratings Changes

TEVA has been the topic of several research analyst reports. Barclays upped their price objective on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Bank of America boosted their target price on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Truist Financial increased their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an “overweight” rating in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $42.00.

Get Our Latest Report on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA opened at $31.81 on Wednesday. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The firm has a market cap of $36.57 billion, a price-to-earnings ratio of 23.92, a P/E/G ratio of 3.28 and a beta of 0.86. The stock’s fifty day moving average price is $33.19 and its two-hundred day moving average price is $32.68. Teva Pharmaceutical Industries has a one year low of $14.99 and a one year high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its earnings results on Wednesday, July 29th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.06). Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The business had revenue of $4.14 billion during the quarter, compared to the consensus estimate of $4.02 billion. Teva Pharmaceutical Industries has set its FY 2026 guidance at 1.910-2.110 EPS. On average, equities analysts forecast that Teva Pharmaceutical Industries will post 1.99 EPS for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at $1,973,727. This represents a 34.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares in the company, valued at $720,576. This represents a 34.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 465,931 shares of company stock worth $16,332,989. Insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors have recently modified their holdings of TEVA. AQR Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after purchasing an additional 4,732 shares in the last quarter. Focus Partners Wealth grew its stake in Teva Pharmaceutical Industries by 4.5% during the first quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after buying an additional 1,739 shares in the last quarter. Franklin Resources Inc. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $255,000. Flow Traders U.S. LLC bought a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $238,000. Finally, Cerity Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 2.9% in the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after buying an additional 1,291 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.